Eoneren/E+ through Getty Images
- Biotech company Scorpius Holdings (NYSE:SCPX) CEO Jeff Wolf mentioned on Monday in a letter to shareholders that the company has recorded a threefold enhance in income for the primary half of 2024.
- Scorpius’ present gross sales pipeline now consists of greater than $100M in alternatives throughout the biopharmaceutical and authorities sectors.
- The company has not too long ago accomplished a spherical of financing, elevating about $14.4M in gross proceeds, Wolf added in his letter.
- The funds will assist Scorpius to supply higher companies and appeal to clients, enabling the biotech company to diversify its buyer base with each industrial and authorities alternatives.
- The company has additionally began transitioning a number of of its key purchasers from course of improvement section into full-scale manufacturing to allow further income stream.
- Shares of Scorpius had been down 3.33% throughout pre-market buying and selling.
More on Scorpius Holdings
Source: Seekingalpha